Tempest Therapeutics Inc

NASDAQ TPST

Data sourced from

and

Download Data

Tempest Therapeutics Inc Days Sales Outstanding (DSO) 1 year YoY Change (%) for the year ending September 20, 2024

Tempest Therapeutics Inc Days Sales Outstanding (DSO) 1 year YoY Change (%) is NA for the year ending September 20, 2024. The days sales outstanding ratio measures the average number of days it takes for a company to collect payment from its customers. It is calculated by dividing receivables by revenue and then multiplying by 365. This ratio indicates the average collection period for accounts receivable and provides insights into the effectiveness of the company's credit and collection policies. A shorter period indicates faster collection and better cash flow management. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: TPST

Tempest Therapeutics Inc

CEO	Mr. Stephen R. Brady J.D., LLM
IPO Date	Nov. 12, 2012
Location	United States
Headquarters	7000 Shoreline Court, South San Francisco, CA, United States, 94080
Employees	17
Sector	Healthcare
Industry	Biotechnology

Description

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Key trends